However, because of the immunosuppressive tumor microenvironments, only a limited portion of cancer patients truly benefit from the immunotherapy.[2] Recent studies have shown that the mutant p53 (mutp53), the commonly observed genetic alterations in over 50% of human cancer,[3] could make contributions to immunosuppressive microenvironments by inhibiting the cGAS‐STING pathway. The gene discussed is TP53; the disease is cancer.